0000899243-20-033215.txt : 20201209
0000899243-20-033215.hdr.sgml : 20201209
20201209195426
ACCESSION NUMBER: 0000899243-20-033215
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201207
FILED AS OF DATE: 20201209
DATE AS OF CHANGE: 20201209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bolzon Bradley J PhD
CENTRAL INDEX KEY: 0001354345
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 201379106
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET
STREET 2: SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-07
0
0001674416
CRISPR Therapeutics AG
CRSP
0001354345
Bolzon Bradley J PhD
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Shares
2020-12-07
4
S
0
4809
144.3926
D
513381
I
See Footnote
Common Shares
2020-12-07
4
S
0
2762
145.4293
D
510619
I
See Footnote
Common Shares
2020-12-07
4
S
0
4203
146.566
D
506416
I
See Footnote
Common Shares
2020-12-07
4
S
0
24077
147.4008
D
482339
I
See Footnote
Common Shares
2020-12-07
4
S
0
12703
148.4475
D
469636
I
See Footnote
Common Shares
2020-12-07
4
S
0
9416
149.409
D
460220
I
See Footnote
Common Shares
2020-12-07
4
S
0
7067
150.5712
D
453153
I
See Footnote
Common Shares
2020-12-07
4
S
0
600
151.3167
D
452553
I
See Footnote
Common Shares
2020-12-07
4
S
0
10098
153.4396
D
442455
I
See Footnote
Common Shares
2020-12-07
4
S
0
4300
154.4054
D
438155
I
See Footnote
Common Shares
2020-12-07
4
S
0
12123
155.3594
D
426032
I
See Footnote
Common Shares
2020-12-07
4
S
0
4457
156.5301
D
421575
I
See Footnote
Common Shares
2020-12-07
4
S
0
8582
157.5383
D
412993
I
See Footnote
Common Shares
2020-12-07
4
S
0
15260
158.4057
D
397733
I
See Footnote
Common Shares
2020-12-07
4
S
0
8453
159.4791
D
389280
I
See Footnote
Common Shares
2020-12-07
4
S
0
9397
160.4975
D
379883
I
See Footnote
Common Shares
2020-12-07
4
S
0
17627
161.5719
D
362256
I
See Footnote
Common Shares
2020-12-07
4
S
0
14270
162.4034
D
347986
I
See Footnote
Common Shares
2020-12-07
4
S
0
800
163.1313
D
347186
I
See Footnote
Common Shares
40648
D
Common Shares
1336088
I
See Footnote
Common Shares
7922
I
See Footnote
Common Shares
1192139
I
See Footnote
Common Shares
34977
I
See Footnote
Common Shares
38772
I
See Footnote
Common Shares
90730
I
See Footnote
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $144.00 to $144.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $145.00 to $145.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $146.00 to $146.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $147.00 to $147.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $148.00 to $148.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $149.00 to $149.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.15 to $151.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.90 to $153.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (10) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $154.05 to $154.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (11) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $155.00 to $155.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (12) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $156.00 to $156.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (13) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $157.01 to $157.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (14) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $158.00 to $158.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (15) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $159.00 to $159.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (16) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $160.01 to $160.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (17) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $161.00 to $161.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (18) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $162.00 to $162.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (19) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $163.00 to $163.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (20) to this Form 4.
These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
s/ Robin L. Praeger, attorney-in-fact for Bradley Bolzon
2020-12-09